Please login to the form below

Not currently logged in
Email:
Password:

cancer costs

This page shows the latest cancer costs news and features for those working in and with pharma, biotech and healthcare.

Keytruda gains NICE clearance in first line bladder cancer

Keytruda gains NICE clearance in first line bladder cancer

Andrew Winterbottom, Founder and CEO of Fight Bladder Cancer, said his  organisation was “absolutely delighted” with the news. ... While the bladder cancer approval is good news for MSD, immunotherapy continues to hold surprises as companies extend

Latest news

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    Will use the platform for new cell-based cancer therapies. Gilead Sciences has claimed another stake in the emerging cell therapy sector with a $3bn agreement to use Sangamo Biosciences ... and cheaper to deliver - an important consideration given the

  • Roche faces Kadcyla pricing pressure in the UK Roche faces Kadcyla pricing pressure in the UK

    Kadcyla costs around £90, 000 per course of treatment and is set to be dropped from the Cancer Drugs Fund after NHS England decided it provided “insufficient value for retention within ... Deborah Lancaster, director at Roche Products, said the

  • Oncology directions Oncology directions

    Many cancer patients are facing severe financial strain, even bankruptcy in some cases. ... 20% of cancer treatment costs.

  • Rise in cancer therapy costs 'unsustainable' says oncologist Rise in cancer therapy costs 'unsustainable' says oncologist

    The rising costs of these drugs do not reflect development costs, nor do they help drive innovation, said Saltz, who noted that the median price of new cancer therapies in the ... predetermined value targets or indication-specific pricing to take into

  • Express Scripts pushes for pay-for-performance in cancer Express Scripts pushes for pay-for-performance in cancer

    The PBM has published an analysis of prescription cancer drug use and costs ahead of the start of the American Society of Clinical Oncology (ASCO) meeting later this week. . ... Cancer drugs made up a third of the medication costs among patients whose

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose. ... Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively.

  • Winning the war against cancer Winning the war against cancer

    on their own, the evidence to support spending, especially where new treatments would add to already expensive cancer treatment costs.'. ... Cancer is an important disease to see [its] impact on the health system.

  • An effective commercial model for cancer care An effective commercial model for cancer care

    Documenting retrospective use of a cancer product and its outcomes in tandem with direct and indirect costs incurred for such use as documented in reimbursement claims and electronic medical records (EMRs) ... Emphasising patient-provider communication

  • The rising prevalence of diabetes in Europe The rising prevalence of diabetes in Europe

    It kills more people than breast cancer and prostate cancer put together and costs society more than all cancers combined.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Medicines personalised for Tom, Dick and Harry

    Are the current development costs for rare diseases and cancer any higher than those for other therapy areas or are the typically high costs of such medications more concerned with offsetting ... There is an increasingly frenetic tug of war over costs

  • Pharma and free medicines: a different perspective

    Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients. ... Breast Cancer Res Treat 2015; 154:591-608; 4. Hotte SJ, et al.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics